We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

UK shares near 52-week lows: 2 I like and 1 I’d avoid

Edward Sheldon has been scanning the FTSE 350 index for shares trading near their 52-week lows and has identified a couple of interesting opportunities.

| More on:
Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Right now, there are about 15 stocks in the FTSE 350 index that are trading within 5% of their 52-week lows. So, there are plenty of opportunities for those who like to buy beaten-up shares.

Of course, not every stock near its 52-week low is worth buying. With that in mind, here’s a look at two I like, and one I don’t.

Should you buy AstraZeneca Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Growth at a reasonable price

One stock that I think looks attractive at current levels is pharma giant AstraZeneca (LSE: AZN).

Earlier this month, it produced Q3 numbers that were ahead of analysts’ estimates.

Meanwhile, it also raised its annual sales and earnings forecast thanks to strong demand for its cancer drugs. It now expects its full-year earnings to grow by at least a low double-digit percentage.

One thing that’s worth pointing out here is that the company recently bought an exclusive license for an oral weight-loss drug. This drug could give revenues a boost going forward as weight-loss drugs are in high demand right now.

As for the valuation, the FTSE 100 company currently has a forward-looking price-to-earnings (P/E) ratio of about 15.

I think that’s an appealing valuation. However, it’s above the market average, which is a risk.

A defensive dividend stock

Sticking with healthcare, I also like Reckitt (LSE: RKT) at current levels. It’s a consumer healthcare company that owns a range of trusted brands including Nurofen, Strepsils, and Durex.

I think Reckitt could play a valuable role within a portfolio in the current environment.

For a start, it’s a ‘defensive’ company. In an economic downturn, people are still going to buy painkillers and cough drops.

Secondly, it sports a 3.5% dividend yield. So, there are multiple sources of return here.

A risk to consider is that consumers could be tempted to trade down to cheaper brands.

A second risk is that, with bond yields rising, consumer staples stocks – which are often seen as ‘bond proxies’ – could lose some of their appeal.

Trading on a forward-looking P/E ratio of 15, however, I like the set-up here.

Facing intense competition

Finally, the stock near 52-week lows I’d avoid right now is ITV (LSE: ITV).

Now, ITV shares are cheap. Currently, the forward-looking P/E ratio is about seven – well below the market average.

However, I think this low valuation reflects the immense challenges this company is facing.

Not only is it facing a downturn in advertising (a large chunk of revenues) but it’s also facing a huge amount of competition from other players in the media space. This is a company that is up against Netflix, Amazon Prime, Disney+, Apple TV, Hayu, YouTube, and more.

And viewing habits are changing rapidly. According to Ofcom, only around 50% of young people now watch any live television.

One thing this stock has going for it is a big dividend yield. At present, the yield is about 8.4%.

However, that’s not enough to tempt me here. I just think the long-term outlook is too murky.

Ed Sheldon has positions in Amazon, Apple, and Reckitt Benckiser Group Plc. The Motley Fool UK has recommended Amazon, Apple, AstraZeneca Plc, ITV, and Reckitt Benckiser Group Plc. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Value Shares

Image of happy young people man and woman in basic clothing thinking and touching chin while looking aside isolated over yellow background
Investing Articles

I asked ChatGPT where Greggs shares might go next and it said… 

Harvey Jones is in two minds about the outlook for Greggs shares and called in artificial intelligence for its view.…

Read more »

Overjoyed exited middle aged married couple giving high five, finishing doing domestic paperwork together at home. Euphoric happy older mature spouses celebrating successful investment or purchase.
Investing Articles

By mid-2027, analysts expect the BT share price to hit…

After surging to 240p in the first half of 2026, the BT share price has slumped below 200p. Will it…

Read more »

Young female analyst working at her desk in the office
Investing Articles

Lloyds shares seem unstoppable — but what do investors need to watch out for?

Lloyds' shares seem to be on an unstoppable march back to their former glory. But what do investors need to…

Read more »

Curtains, happy woman and thinking of future in home, planning and reflection of mindset with view. Window, smile and African girl with vision, ideas and dream for morning inspiration in living room.
Investing Articles

Up 36% in 3 months! Is this beaten-down FTSE 100 growth stock finally ready to rocket?

Sensing a bargain, Harvey Jones snapped up this growth stock whose shares have fallen by half. Suddenly things are starting…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Stop obsessing over the SpaceX crash and feast your eyes on booming Lloyds shares instead

In all the excitement over US tech stocks like SpaceX, Harvey Jones fears investors will overlook brilliant home-grown successes like…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

What’s the forecast for Lloyds shares in 2027?

Lloyds' shares are locked in a strong upward trend at the moment. And City analysts expect the trend to continue…

Read more »

Close-up of British bank notes
Investing Articles

At a 5-year high, here’s where the experts think the Barclays share price will go next…

Alan Oscroft highlights the case for further Barclays share price progress, and thinks we could still be looking at good…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Near 5-year lows, here’s what the experts say about Greggs shares

Greggs’ shares went from a powerful growth story in 2024 to one of the FTSE 250’s worst-performing shares. Do experts…

Read more »